Boston Scientific Impresses at Investor Day with Three-Year Plan
UBS analysts raise the price target from $135 to $140 (Buy)
Worldwide, 60 million people are affected by atrial fibrillation
Reading Time: 1 minute
Boston Scientific (BSX) is an exciting option for me to play the growing medical technology market for several reasons. At the investor day, it was announced that from 2026 to 2028, there would be an organic growth of 10% per annum and double-digit increases in net profit. UBS also sees a 40% chance of this, maintaining that there is a "most positive product cycle across the entire large-cap MedTech sector." Starting from the 200-day moving average, the all-time high could now be targeted. In Q3, WATCHMAN and FARAPULSE FPA were important drivers....
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
